Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.
Sarah M H EinerhandAnna J BlackHomayoun ZargarAdrian S FaireyColin P DinneyMaria C MirLaura-Maria KrabbeMichael S CooksonNiels-Erik JacobsonJeffrey S MontgomeryNikhil VasdevEvan Y YuEvanguelos XylinasWassim KassoufMarc A Dall'EraSrikala S SridharJonathan S McGrathJonathan AningShahrokh F ShariatJonathan L WrightAndrew C ThorpeTodd M MorganJeff M HolzbeierleinTrinity J BivalacquaScott NorthDaniel A BarocasYair LotanPetros GrivasJorge A GarciaAndrew J StephensonJay B ShahSiamak DaneshmandKamran Zargar-ShoshtariPhilippe E SpiessBas W G van RhijnPeter C BlackLaura S MertensPublished in: World journal of urology (2022)
Our results show that a subset of cisplatin-ineligible patients with MIBC achieve pCR on gem-carbo and that survival outcomes seem comparable to gem-cis provided patients are able to receive ≥ 3 cycles and undergo RC.